Trending Now
bluebird bio Inc (NASDAQ: BLUE) Announces Q2 2022 Financial Results And...
bluebird bio Inc (NASDAQ: BLUE) has announced its Q2 2022 financial results and offered business highlights for the quarter ending June 30, 2022.
bluebird bio...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Acer Therapeutics Inc (NASDAQ: ACER) Announces Breakthrough Therapy Designation For Celiprolol
Acer Therapeutics Inc (NASDAQ: ACER) has announced that its celiprolol therapy has received Breakthrough Therapy Designation from the FDA. The company has developed Celiprolol...
MAKE IT MODERN
LATEST REVIEWS
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Enters Manufacturing And Supply Agreement With...
A subsidiary of Axovant Gene Therapies Ltd (NASDAQ:AXGT) entered a 3-year pact with Oxford BioMedica Plc (OTCMKTS:OXBDF) for the manufacture and supply of GMP...
MAKE IT MODERN
PERFORMANCE TRAINING
Briacell Therapeutics Corp (NASDAQ: BCTX) Receives the Fast Track Designation For Bria-IMT
Briacell Therapeutics Corp (NASDAQ: BCTX) has received U.S FDA Fast Track Designation for Bria-IMT. This therapy is for metastatic breast cancer. The company is...
Sorrento Therapeutics Inc (NASDAQ: SRNE) Reports Positive Findings From Abivrtinib Study in Heavily Pre-treated...
Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced positive findings from its pivotal Abivertinib study in 209 response-valued, highly pretreated patients with NSCLC through an...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) Announces Fast Track Designation to BDTX-189 from the FDA...
There are hundreds of adult patients under the affliction of solid tumors harboring an allosteric HER2 mutation or an EGFR or HER2 exon 20...
Auris Medical Holding Ltd (NASDAQ: EARS) Clinches Trasir To Concentrate On RNA Therapeutics Development
Auris Medical Holding Ltd (NASDAQ: EARS) took over Trasir Therapeutics, Inc to concentrate on RNA Therapeutics development.
Inducts Samuel Wickline as CSO
The company will assume...
Incyte (NASDAQ:INCY) Reports Exceptional Performance In Q3 Thanks To Jakavi® Sales
Incyte (NASDAQ:INCY) has announced Q3 financial results and provided a status update on its development portfolio.
The company reported a 16% YoY growth in total...
MAKE IT MODERN
